Journal: Oncology letters

Article Title: Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia.

doi: 10.3892/ol.2021.13125

Figure Lengend Snippet: Figure 5. Effects of Tan and Im on BCR/ABL signaling and apoptosis‑regulatory proteins in Philadelphia chromosome‑positive acute lymphoblastic leukemia. SUP‑B15 cells were treated with 0.1% DMSO (control), 2 µM Im, 4 µM Tan or the combination of 2 µM Im and 4 µM Tan for 24 and 48 h. SUP‑B15/RI cells were treated with 0.1% DMSO (control), 10 µM Im, 8 µM Tan or the combination of 10 µM Im and 8 µM Tan for 24 h and 48 h. At the end of the treatments, the cells were collected, and the total proteins were extracted for western blot analysis using the corresponding antibodies. One representative western blot is presented. GAPDH was used as the loading control. (A) Effects of Tan and Im on the activation of BCR/ABL, STAT5 and MEK in SUP‑B15 cells. (B) Effects of Tan and Im on the activation of BCR/ABL, STAT5 and MEK in SUP‑B15/RI cells. (C) Effects of Tan and Im on the anti‑apoptotic proteins BCL2 and MCL1 in SUP‑B15. (D) Effects of Tan and Im on the anti‑apoptotic proteins BCL2 and MCL1 in SUP‑B15/RI. Im, imatinib; MCL1, MCL1 apoptosis regulator, BCL2 family member; p‑, phosphorylated; Tan, tanshinone IIA.

Article Snippet: The antibody against MCL1 apoptosis regulator, BCL2 family member (MCL1) was purchased from OriGene Technologies, Inc.

Techniques: Control, Western Blot, Activation Assay